EARNEST Partners’s Sage Therapeutics SAGE Stock Holding History

EARNEST Partners’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-24	Closed	-$494	–	943
2023 Q3	$494	Hold	24	–	–	﹤0.01%	1118
2023 Q2	$1.13K	Hold	24	–	–	﹤0.01%	1061
2023 Q1	$1.01K	Hold	24	–	–	﹤0.01%	1063
2022 Q4	$915	Hold	24	–	–	﹤0.01%	1090
2022 Q3	$1K	Hold	24	–	–	﹤0.01%	1079
2022 Q2	$1K	Hold	24	–	–	﹤0.01%	1100
2022 Q1	$1K	Hold	24	–	–	﹤0.01%	1109
2021 Q4	$1K	Hold	24	–	–	﹤0.01%	1126
2021 Q3	$1K	Hold	24	–	–	﹤0.01%	1130
2021 Q2	$1K	Hold	24	–	–	﹤0.01%	1134
2021 Q1	$2K	Hold	24	–	–	﹤0.01%	1056
2020 Q4	$2K	Hold	24	–	–	﹤0.01%	1036
2020 Q3	$1K	Hold	24	–	–	﹤0.01%	1096
2020 Q2	$1K	Hold	24	–	–	﹤0.01%	1078
2020 Q1	$1K	Hold	24	–	–	﹤0.01%	1032
2019 Q4	$2K	Hold	24	–	–	﹤0.01%	1022
2019 Q3	$3K	Hold	24	–	–	﹤0.01%	923
2019 Q2	$4K	Hold	24	–	–	﹤0.01%	849
2019 Q1	$4K	Hold	24	–	–	﹤0.01%	854
2018 Q4	$2K	Hold	24	–	–	﹤0.01%	998
2018 Q3	$3K	Hold	24	–	–	﹤0.01%	961
2018 Q2	$4K	Buy	+24	New	+$3.77K	﹤0.01%	867

Other funds holding SAGE

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EARNEST Partners's SAGE Position: Q4 2023 in Review

EARNEST Partners sold out of Sage Therapeutics (SAGE) in Q4 2023, closing a stake of 24 shares — an estimated $494 sold.

EARNEST Partners first reported a position in SAGE in Q2 2018 and held it in 22 quarters. The position peaked at $4K in Q2 2019. 201 funds tracked by Wall St. Rank hold SAGE as of Q4 2023.

EARNEST Partners reported no remaining Sage Therapeutics position as of Q4 2023 after selling out during the quarter.
EARNEST Partners sold 24 Sage Therapeutics shares in Q4 2023, an estimated $494.
EARNEST Partners first reported a position in Sage Therapeutics in Q2 2018 and held it in 22 quarters.
EARNEST Partners's Sage Therapeutics position peaked at $4K in Q2 2019.
201 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2023.

Based on EARNEST Partners's 13F filing for Q4 2023, filed 14 Feb 2024.